News: cancer research
SAiGENCI recruit recognised with prestigious award
Professor Jenkins has been appointed as the Program Head for the Tumour Inflammation and Immunotherapy Program at the South Australian ImmunoGENomics Cancer Institute (SAiGENCI), which operates within the University of Adelaide’s Faculty of Health and Medical Sciences, and is supported by an alliance with the Central Adelaide Local Health Network (CALHN).
[Read more about SAiGENCI recruit recognised with prestigious award]
Towards the future: improving survivorship for children with brain cancer
Brain cancer is the most common solid tumour of childhood and most lethal type of cancer in Australian children.
[Read more about Towards the future: improving survivorship for children with brain cancer]
Unlocking the mysteries of prostate cancer
The SAiGENCI team is creating a comprehensive data repository and applying machine learning to uncover revolutionary insights for prostate cancer treatment and prevention.
[Read more about Unlocking the mysteries of prostate cancer]
ENZAMET shows promise as prostate cancer treatment
The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI) that operates within the University of Adelaide, have been published today in The Lancet Oncology .
[Read more about ENZAMET shows promise as prostate cancer treatment ]
Top talent to boost cancer research
The search for a tailored treatment for cancerous tumours has been bolstered with the appointment of an internationally recognised expert to the South Australian immunoGENomics Cancer Institute (SAiGENCI).
